Affimed appoints Shawn Leland as Chief Executive Officer

Affimed announced today that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer CEO . Dr. Andreas Harstrick, who has been serving as acting CEO since January 2024 will continue in his position as Chief Medical Officer CMO .”Affimed has an impressive pipeline of three clinical stage assets, that have all delivered clinical proof of concept and have validated the company’s strategy to harness the innate immune system to fight cancer,” said Shawn Leland. “These data together with the successful transformation of the organization were central to my decision to join the team. I am eager to lead Affimed toward meaningful inflection points so that these much-needed novel therapies reach those currently underserved patients and increase value for our shareholders.”